Kanavit (Phytomenadione)

Phytomenadione serves as a cofactor for the enzyme that adds a carboxyl group to specific glutamate residues in clotting factors II, VII, IX and X. This gamma‑carboxylation enables the factors to bind calcium, a critical step for assembling the clotting cascade and generating thrombin, thereby restoring hemostasis.

The appropriate dose of Kanavit is determined by the prescribing clinician based on the patient’s condition, age, weight, and laboratory values. Dosage regimens can vary widely, so the prescriber sets the exact amount and schedule for each individual case.

Kanavit may be used during pregnancy only if the potential benefit justifies any possible risk to the fetus, and it should be prescribed by a qualified healthcare professional. While limited data exist for breastfeeding, caution is advised and a clinician should evaluate the risk‑benefit balance for the infant.

To request Kanavit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kanavit provides phytomenadione in an oral dosage form, similar to other vitamin K1 (phytonadione) preparations. Compared with injectable forms, oral Kanavit offers convenient administration for outpatient settings but may have slower onset of action. Efficacy and safety profiles are comparable when used according to clinical guidelines.

Kanavit should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures, which could affect potency.

Kanavit is taken orally, typically with water. The exact administration instructions, including whether it should be taken with food or on an empty stomach, are provided by the prescribing healthcare professional based on the individual treatment plan.

Serious risks, though rare, include anaphylactic reactions, severe hypersensitivity with angioedema, and unexpected severe bleeding despite therapy. Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, swelling of the face or throat, or sudden extensive bruising.

Kanavit is contraindicated in individuals with known hypersensitivity to phytomenadione or any excipients in the formulation. Patients with a history of severe allergic reactions to vitamin K products should avoid its use, and clinicians should assess suitability for each patient.